China Innovative Device Special Review Pathway

1. Key takeaways

The innovative device special review is a procedural arrangement made before acceptance, not a licence, and it changes access to reviewers rather than the standard they apply.

• It is a pre-acceptance arrangement, not the licence itself. Under the Special Review Procedure for Innovative Medical Devices (NMPA Announcement No. 83 of 2018, published 2 November 2018, effective 1 December 2018), the application must precede the first registration application; success brings channel eligibility, not a licence.
• The patent test is hard, and it is a test of timing. A core technology invention patent is the central condition, within an application window that GRZAN assesses against five years as a practical estimate.
• Early intervention and a dedicated reviewer are the mechanism features that distinguish it from routine review, moving review resources forward.
• Early intervention changes the rhythm of communication, not the standard. Innovative status exempts nothing: clinical evaluation, non-clinical research, technical requirements and quality system inspection all still apply.
• Special and priority approval are parallel channels under Article 10 of Order 47 (promulgated 26 August 2021, effective 1 October 2021).
• Channel use is measurable. In 2025, 76 innovative devices were approved, up 17 percent, for a cumulative 361 (2025 Annual Medical Device Registration Report, NMPA, 24 February 2026).
• There is a clear fee benefit. Under the NMPA licensing fee catalogue, registration applications for innovative devices from small and micro enterprises are free.

2. Legal basis

Regulations on the Supervision and Administration of Medical Devices (State Council Decree No. 739, promulgated 9 February 2021, effective 1 June 2021)

• Article 5: supervision follows the principles of risk management, whole-process control, scientific oversight and social co-governance.
• Article 6: devices are classified by risk.
• Article 14: seven categories of registration and filing material, the fourth being clinical evaluation material.

Opinions of the General Office of the State Council on Deepening Reform of Drug and Device Supervision (Guobanfa 2024 No. 53, issued 30 December 2024)

Provisions for the Administration of Medical Device Registration and Filing (SAMR Order No. 47, promulgated 26 August 2021, effective 1 October 2021)

• Article 5: the Center for Medical Device Evaluation (CMDE) handles technical review of domestic Class III and imported Class II and III applications, variations and renewals, and of trial applications requiring approval.
• Article 10: the NMPA applies special approval to innovative devices and priority approval to devices in urgent clinical need.
• Article 22: technical bodies shall establish a communication system.
• Article 23: the expert consultation system.
• Article 41: deficiencies notified in full at one time, answered within one year, otherwise review is terminated and approval refused.
• Article 120: fee items and standards follow State Council finance and pricing rules.

Normative and technical documents

• Special Review Procedure for Innovative Medical Devices (Announcement No. 83 of 2018, published 2 November 2018, effective 1 December 2018): Articles 2 and 3 set the conditions, the core patent requirement and the review arrangements.
• Announcement on Measures to Optimise Whole-Life-Cycle Supervision and Support High-End Device Innovation (No. 63 of 2025, issued 27 June 2025).
• 2025 Annual Medical Device Registration Report (NMPA, 24 February 2026): 76 innovative devices approved in 2025, up 17 percent.
• Fees: no charge for innovative device registration applications from small and micro enterprises.

Practical estimate. No official figure exists for the review cycle, the number of feedback rounds, or provincial Class II fees. Some provinces publish RMB 40,670 per registration unit. The start point and exceptions of the patent window follow Announcement No. 83 of 2018; borderline cases should be confirmed through the communication channel.

3. Expert insights

Innovative review delivers a channel, not an outcome. Companies often expect faster approval. What changes is the allocation of review resources and the communication mechanism, not the standard.

The third row matters. Innovative status exempts neither the seven categories of material nor clinical evaluation nor system inspection. Treating it as a relaxation lowers the file standard, and the cost is paid in technical review.

The patent threshold is about timing, not merely possession. Articles 2 and 3 of Announcement No. 83 make the core technology invention patent the central condition, , assessed by three questions: does it cover the core technology rather than a peripheral structure or appearance; is title clear, whether held or assigned; and is it within the window, treated in industry practice as five years. Products most often fail the third. Long development cycles mean patents are filed years before the product is finalised, so the window has closed by the time an application is possible. The filing date should therefore be planned during patent layout.

Filing must precede the first registration application, and that point is irreversible. Once a registration application is submitted, eligibility for special review is lost. This creates tension with project rhythm: completeness usually means being close to submission. The filing point should sit where the technical solution is fixed and the main non-clinical work is complete but no application has been filed, with the decision recorded.

Early intervention reduces rework rather than statutory time. Its value concentrates in three situations: an uncertain pathway, where the need for a trial or the choice among clinical evaluation routes can be settled early; drafting of technical requirements, where indicator setting and test methods can be discussed; and a contested definition of the innovative element, where the link to technical risk can be aligned. All three reduce rework from directional disagreement. Statutory review time is not shortened.

Approval numbers show the channel is routine. The 2025 report records 76 innovative devices approved, up 17 percent, and 361 cumulative. The channel therefore operates as a standing mechanism rather than a scarce quota, and the question is whether the conditions are met, especially the patent condition. One distinction matters when citing the figures: approved innovative devices reached the market, while passing special review means obtaining channel eligibility.

Fee relief and channel eligibility are independent. The fee catalogue waives charges for innovative device applications from small and micro enterprises, which requires two determinations: innovative status under Announcement No. 83, and small or micro status under the current catalogue. Where relief does not apply, the domestic Class III benchmarks are RMB 153,600 for initial registration, RMB 50,400 for variation and RMB 40,800 for renewal.

4. Practical recommendations

• Check patent status before discussing filing, using the three questions on core technology, title and window.
• Fix the filing point early, between a settled technical solution and an unfiled application, and keep the decision record.
• Separate innovative status from documentation standards, making clear internally that channel eligibility does not change the review standard.
• Prepare a short agenda for early communication covering the clinical pathway, technical requirements and the innovative element to risk link.
• Assess the priority channel at the same time, since Article 10 of Order 47 sets the two side by side.
• Verify fees as two separate questions, with a budget based on RMB 153,600 for a domestic Class III initial registration.
• Name a single contact person to work with the dedicated reviewer and avoid inconsistent positions.
• Prepare in parallel on the routine route, since the outcome is uncertain and the file should not stall.

5. Verification checklist

• □ Ownership of the core technology patent is verified, whether held or assigned.
• □ The patent window has been judged against Announcement No. 83 and has not expired.
• □ The filing point precedes the first application, with the decision recorded.
• □ Eligibility for both the special and priority channels has been assessed (Article 10).
• □ An agenda for early communication covers pathway, technical requirements and risk linkage.
• □ Innovative status exempts no clinical, non-clinical or system requirement.
• □ One internal contact is named for the dedicated reviewer.
• □ Small or micro status and fee relief are verified against the current catalogue.
• □ The budget reflects RMB 153,600 initial, RMB 50,400 variation and RMB 40,800 renewal.
• □ Routine-route preparation and progress tracking run in parallel.
• □ The response plan follows the one-year limit (Article 41).
• □ Figures distinguish approved devices from those passing special review.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Chinese market. Our team manages NMPA Class II/III registrations and filing procedures, coordinates typetesting, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com